Table 37Sensitivity Analysis Regarding Cost of Emerging Treatments

TreatmentEstimated
Annual cost
λ = $50,000
(ICUR versus glatiramer
acetate)
λ = $100,000
(ICUR versus glatiramer
acetate)
Alemtuzumab 12 mg$40,281a$21,900$25,000
Alemtuzumab 24 mg$40,281a$23,550$26,950
Teriflunomide 14 mg$24,184b$16,420$16,650

ICUR = incremental cost-utility ratio; mg = milligram.

a

Assumption, based on the price of natalizumab.

b

Assumption, based on the US price.

From: 4, RESULTS

Cover of Comparative Clinical and Cost-Effectiveness of Drug Therapies for Relapsing-Remitting Multiple Sclerosis
Comparative Clinical and Cost-Effectiveness of Drug Therapies for Relapsing-Remitting Multiple Sclerosis [Internet].
CADTH Therapeutic Review, No. 1.2B.
Copyright © CADTH March 2013.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.